Drug Type Small molecule drug |
Synonyms ORIN 1001, ORIN1001 |
Target |
Action inhibitors |
Mechanism IRE1 inhibitors(Serine/threonine-protein kinase/endoribonuclease IRE1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
RegulationFast Track (United States) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Breast Cancer | Phase 2 | China | 30 Jan 2022 | |
Advanced Malignant Solid Neoplasm | Phase 2 | China | 01 Jul 2020 | |
Solid tumor | Phase 2 | China | - | |
Idiopathic Pulmonary Fibrosis | Phase 1 | United States | - | |
Idiopathic Pulmonary Fibrosis | Phase 1 | China | - |
Phase 1/2 | 43 | tftyafscfp(znskwfthge) = eeubvpqazm nkeamjpwcc (gpklhbkeye ) View more | Positive | 26 May 2023 | |||
tftyafscfp(znskwfthge) = deydsfzawo nkeamjpwcc (gpklhbkeye ) View more | |||||||
Phase 1 | 22 | iqvcpuadag(qshbruzarf) = fvoktchccc kxmbjpikpn (sybtjcaknw ) | - | 28 May 2021 |